Identification of B94 (TNFAIP2) as a potential retinoic acid target gene acute promyelocytic leukemia

Michael E. Rusiniak, Min Yu, Douglas T. Ross, Erin C. Tolhurst, James L Slack

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Acute promyelocytic leukemia (APL) is characterized by a block to myeloid differentiation caused by expression of the fusion oncoprotein promyelocytic leukemia-retinoic acid receptor α (PML-RARα). The purpose of this study was to identify genes that are regulated in a PML-RARα-dependent fashion by retinoic acid (RA), because such genes may be integrally involved in APL pathogenesis and/or myeloid differentiation. A cDNA microarray approach was used to identify genes induced in response to RA in TF1 myeloid leukemia cells expressing PML-RARα (TF1-PR cells). The B94 gene (TNFAIP2; Unigene Hs.101382), originally identified as a tumor necrosis factor α- inducible gene in endothelial cells, was one of several genes found to be induced by RA specifically in TF1-PR cells, but not in TF1-neo (control) cells. The induction of B94 was most pronounced in cells expressing the PML- RARα short isoform and was negligible in cells that expressed a mutant PML- RARα protein containing a deletion of the PML coiled-coil domain. B94 induction by RA occurred within 1 h, did not require new protein synthesis, and was inhibited by actinomycin D, suggesting rapid transcriptional activation. B94 was also induced by RA in NB4, UF1, and HL-60 cells, but not in other hematopoietic cell lines tested, suggesting that its up-regulation by RA may be specific to cells that express PML-RARα or are at the late myeloblast or promyelocyte stage of myeloid development. A screen of bone marrow cells from normal donors or patients with acute myelogenous leukemia showed that B94 was highly expressed in normal marrow and in marrow from patients with acute myelogenous leukemia French-American-British subtypes M0-M2, but was repressed in marrow cells from APL patients. Treatment of APL blasts in vitro with all-trans-RA resulted in up-regulation of B94 mRNA. These results suggest that B94 plays a role in myeloid development and support the hypothesis that B94 is a target gene of PML-RARα in APL.

Original languageEnglish (US)
Pages (from-to)1824-1829
Number of pages6
JournalCancer Research
Volume60
Issue number7
StatePublished - Apr 1 2000
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Retinoic Acid Receptors
Leukemia
Genes
Granulocyte Precursor Cells
Bone Marrow
Acute Myeloid Leukemia
Up-Regulation
Myeloid Leukemia
HL-60 Cells
Oncogene Proteins
Dactinomycin
Myeloid Cells
Oligonucleotide Array Sequence Analysis
Bone Marrow Cells
Transcriptional Activation
Protein Isoforms
Proteins
Endothelial Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of B94 (TNFAIP2) as a potential retinoic acid target gene acute promyelocytic leukemia. / Rusiniak, Michael E.; Yu, Min; Ross, Douglas T.; Tolhurst, Erin C.; Slack, James L.

In: Cancer Research, Vol. 60, No. 7, 01.04.2000, p. 1824-1829.

Research output: Contribution to journalArticle

Rusiniak, ME, Yu, M, Ross, DT, Tolhurst, EC & Slack, JL 2000, 'Identification of B94 (TNFAIP2) as a potential retinoic acid target gene acute promyelocytic leukemia', Cancer Research, vol. 60, no. 7, pp. 1824-1829.
Rusiniak, Michael E. ; Yu, Min ; Ross, Douglas T. ; Tolhurst, Erin C. ; Slack, James L. / Identification of B94 (TNFAIP2) as a potential retinoic acid target gene acute promyelocytic leukemia. In: Cancer Research. 2000 ; Vol. 60, No. 7. pp. 1824-1829.
@article{85f8f3128a834bee9fe0805fe396b67d,
title = "Identification of B94 (TNFAIP2) as a potential retinoic acid target gene acute promyelocytic leukemia",
abstract = "Acute promyelocytic leukemia (APL) is characterized by a block to myeloid differentiation caused by expression of the fusion oncoprotein promyelocytic leukemia-retinoic acid receptor α (PML-RARα). The purpose of this study was to identify genes that are regulated in a PML-RARα-dependent fashion by retinoic acid (RA), because such genes may be integrally involved in APL pathogenesis and/or myeloid differentiation. A cDNA microarray approach was used to identify genes induced in response to RA in TF1 myeloid leukemia cells expressing PML-RARα (TF1-PR cells). The B94 gene (TNFAIP2; Unigene Hs.101382), originally identified as a tumor necrosis factor α- inducible gene in endothelial cells, was one of several genes found to be induced by RA specifically in TF1-PR cells, but not in TF1-neo (control) cells. The induction of B94 was most pronounced in cells expressing the PML- RARα short isoform and was negligible in cells that expressed a mutant PML- RARα protein containing a deletion of the PML coiled-coil domain. B94 induction by RA occurred within 1 h, did not require new protein synthesis, and was inhibited by actinomycin D, suggesting rapid transcriptional activation. B94 was also induced by RA in NB4, UF1, and HL-60 cells, but not in other hematopoietic cell lines tested, suggesting that its up-regulation by RA may be specific to cells that express PML-RARα or are at the late myeloblast or promyelocyte stage of myeloid development. A screen of bone marrow cells from normal donors or patients with acute myelogenous leukemia showed that B94 was highly expressed in normal marrow and in marrow from patients with acute myelogenous leukemia French-American-British subtypes M0-M2, but was repressed in marrow cells from APL patients. Treatment of APL blasts in vitro with all-trans-RA resulted in up-regulation of B94 mRNA. These results suggest that B94 plays a role in myeloid development and support the hypothesis that B94 is a target gene of PML-RARα in APL.",
author = "Rusiniak, {Michael E.} and Min Yu and Ross, {Douglas T.} and Tolhurst, {Erin C.} and Slack, {James L}",
year = "2000",
month = "4",
day = "1",
language = "English (US)",
volume = "60",
pages = "1824--1829",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Identification of B94 (TNFAIP2) as a potential retinoic acid target gene acute promyelocytic leukemia

AU - Rusiniak, Michael E.

AU - Yu, Min

AU - Ross, Douglas T.

AU - Tolhurst, Erin C.

AU - Slack, James L

PY - 2000/4/1

Y1 - 2000/4/1

N2 - Acute promyelocytic leukemia (APL) is characterized by a block to myeloid differentiation caused by expression of the fusion oncoprotein promyelocytic leukemia-retinoic acid receptor α (PML-RARα). The purpose of this study was to identify genes that are regulated in a PML-RARα-dependent fashion by retinoic acid (RA), because such genes may be integrally involved in APL pathogenesis and/or myeloid differentiation. A cDNA microarray approach was used to identify genes induced in response to RA in TF1 myeloid leukemia cells expressing PML-RARα (TF1-PR cells). The B94 gene (TNFAIP2; Unigene Hs.101382), originally identified as a tumor necrosis factor α- inducible gene in endothelial cells, was one of several genes found to be induced by RA specifically in TF1-PR cells, but not in TF1-neo (control) cells. The induction of B94 was most pronounced in cells expressing the PML- RARα short isoform and was negligible in cells that expressed a mutant PML- RARα protein containing a deletion of the PML coiled-coil domain. B94 induction by RA occurred within 1 h, did not require new protein synthesis, and was inhibited by actinomycin D, suggesting rapid transcriptional activation. B94 was also induced by RA in NB4, UF1, and HL-60 cells, but not in other hematopoietic cell lines tested, suggesting that its up-regulation by RA may be specific to cells that express PML-RARα or are at the late myeloblast or promyelocyte stage of myeloid development. A screen of bone marrow cells from normal donors or patients with acute myelogenous leukemia showed that B94 was highly expressed in normal marrow and in marrow from patients with acute myelogenous leukemia French-American-British subtypes M0-M2, but was repressed in marrow cells from APL patients. Treatment of APL blasts in vitro with all-trans-RA resulted in up-regulation of B94 mRNA. These results suggest that B94 plays a role in myeloid development and support the hypothesis that B94 is a target gene of PML-RARα in APL.

AB - Acute promyelocytic leukemia (APL) is characterized by a block to myeloid differentiation caused by expression of the fusion oncoprotein promyelocytic leukemia-retinoic acid receptor α (PML-RARα). The purpose of this study was to identify genes that are regulated in a PML-RARα-dependent fashion by retinoic acid (RA), because such genes may be integrally involved in APL pathogenesis and/or myeloid differentiation. A cDNA microarray approach was used to identify genes induced in response to RA in TF1 myeloid leukemia cells expressing PML-RARα (TF1-PR cells). The B94 gene (TNFAIP2; Unigene Hs.101382), originally identified as a tumor necrosis factor α- inducible gene in endothelial cells, was one of several genes found to be induced by RA specifically in TF1-PR cells, but not in TF1-neo (control) cells. The induction of B94 was most pronounced in cells expressing the PML- RARα short isoform and was negligible in cells that expressed a mutant PML- RARα protein containing a deletion of the PML coiled-coil domain. B94 induction by RA occurred within 1 h, did not require new protein synthesis, and was inhibited by actinomycin D, suggesting rapid transcriptional activation. B94 was also induced by RA in NB4, UF1, and HL-60 cells, but not in other hematopoietic cell lines tested, suggesting that its up-regulation by RA may be specific to cells that express PML-RARα or are at the late myeloblast or promyelocyte stage of myeloid development. A screen of bone marrow cells from normal donors or patients with acute myelogenous leukemia showed that B94 was highly expressed in normal marrow and in marrow from patients with acute myelogenous leukemia French-American-British subtypes M0-M2, but was repressed in marrow cells from APL patients. Treatment of APL blasts in vitro with all-trans-RA resulted in up-regulation of B94 mRNA. These results suggest that B94 plays a role in myeloid development and support the hypothesis that B94 is a target gene of PML-RARα in APL.

UR - http://www.scopus.com/inward/record.url?scp=0034074311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034074311&partnerID=8YFLogxK

M3 - Article

C2 - 10766166

AN - SCOPUS:0034074311

VL - 60

SP - 1824

EP - 1829

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -